Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ArcticZymes Technologies ASA ( (DE:B4V) ) just unveiled an announcement.
ArcticZymes Technologies has released a new white paper detailing a viral vector manufacturing cost model that underscores the economic impact of nuclease choice in cell and gene therapy production. Built on experimentally validated AAV and lentiviral workflows, the analysis shows that adopting salt-active nuclease strategies can materially improve downstream performance and lower cost per dose.
The model suggests optimized nuclease selection can roughly double overall process recovery, cut nuclease-related costs per batch by more than 70%, and reduce cost of goods per dose by about 40%. Beyond direct savings, the paper highlights gains in downstream robustness, filtration performance and regulatory confidence, positioning nuclease strategy as a strategic lever for manufacturers seeking more scalable and affordable viral vector-based therapies.
More about ArcticZymes Technologies ASA
ArcticZymes Technologies ASA is a Norwegian life sciences company specializing in the development, manufacturing and commercialization of novel recombinant enzymes used in molecular research, in vitro diagnostics and biomanufacturing. Listed on the Oslo Stock Exchange and headquartered in Tromsø, the company serves global advanced therapy and bioprocessing markets, supported by a broad patent portfolio protecting its enzyme technologies.
Average Trading Volume: 62,564
Current Market Cap: NOK1.17B
For a thorough assessment of B4V stock, go to TipRanks’ Stock Analysis page.